Surgery Doctors in Hamden, CT Accepting Medicare

5 Surgery doctors found. Showing 1 - 5

Rae Lynne Poirrier Kinler, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 2590 Whitney Ave, Unit 2, Hamden, CT 06518 Phone: 225-806-1184

Julia Zakhaleva, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 2200 Whitney Ave, Suite 220, Hamden, CT 06518 Phone: 203-281-7000    Fax: 203-281-9300

Dr. John Anthony Bonadies, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 2200 Whitney Ave Ste 170, Hamden, CT 06518 Phone: 203-281-7000    Fax: 203-909-6782

Christopher Husko, DO Surgery Medicare: Accepting Medicare Assignments Practice Location: 2200 Whitney Ave Ste 170, Hamden, CT 06518 Phone: 203-281-7000

Dr. Deborah Keller, MD Surgery Medicare: Medicare Enrolled Practice Location: 2200 Whitney Ave Ste 170, Hamden, CT 06518 Phone: 203-281-7000    Fax: 203-909-6782

News Archive

OHSU study shows better clinical outcomes for deep brain stimulation while patients are asleep

Deep brain stimulation is a long-established surgical procedure that eases the effects of Parkinson's disease and essential tremor through pulses from tiny electrodes implanted in the brain. Currently, most surgeons around the world conduct this surgery while the patient is awake.

How well do fabric face masks protect from COVID?

In a new study, published on the pre-print server medRxiv, researchers at the University of Cambridge found that fabric face masks block 62.6 percent to 87.1 percent of fine particles, making them useful tools in the battle against the COVID-19 pandemic.

Improving cancer therapy achieved through taste, odor intervention

Cancer and its therapies, including chemotherapy and radiotherapy, may directly alter and damage taste and odor perception, possibly leading to patient malnutrition, and in severe cases, significant morbidity, according to a Virginia Tech - Wake Forest University Comprehensive Cancer Center compilation of various existing studies.

Nile Therapeutics to sell 3.6 million shares of common stock

Nile Therapeutics, Inc., a biopharmaceutical company that develops novel therapeutics for heart failure patients, today announced that it has entered into a definitive agreement to sell 3.6 million shares of its common stock at a price per share of $0.40 for aggregate gross proceeds of $1.44 million.

Reliable and relevant information needed to rein in the costs of federal health-care programs, says study

For economists and policy-makers to understand the true value of the costs and savings of preventive health programs for chronic disease, the Congressional Budget Office (CBO) should incorporate long-term clinical outcomes data and look beyond the 10-year window when making cost estimates, says a team of University of Chicago researchers in today's issue of Health Affairs.

Read more Medical News

› Verified 6 days ago